menu
    • menu

    Company profile for CutisPharma, Inc

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CutisPharma, Inc., based in Wilmington, Massachusetts, is a privately held, specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications for nearly 20 years. The Company’s products include oral solutions and suspensions, such as antimicrobials, mouthwashes, and PPIs; topicals, including hydrocortisone; and progesterone suppositories. The Com...
    CutisPharma, Inc., based in Wilmington, Massachusetts, is a privately held, specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications for nearly 20 years. The Company’s products include oral solutions and suspensions, such as antimicrobials, mouthwashes, and PPIs; topicals, including hydrocortisone; and progesterone suppositories. The Company’s FI℞ST® Unit-of-Use Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs were not served by commercially available therapies. Building on the strength of its legacy compounding product portfolio, the Company has recently prioritized its focus toward developing and commercializing FDA-approved drugs in niche markets of high-unmet need

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CutisPharma, IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    841 Woburn Street, Wilmington, MA 01887
    Telephone
    Telephone
    800-461-7449
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cutispharma.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/cutispharma-inc.
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Newly-Branded Azurity Wins FDA Approval for Liquid Form of Amlodipine
    Newly-Branded Azurity Wins FDA Approval for Liquid Form of Amlodipine

    10 Jul 2019

    // Alex Keown BIOSPACE

    https://www.biospace.com/article/newly-branded-azurity-wins-fda-approval-for-liquid-form-of-amlodipine/

    Alex Keown BIOSPACE
    10 Jul 2019
    Share Share
    CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals
    CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals

    12 Jun 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cutispharma-announces-acquisition-of-silvergate-pharmaceuticals-name-change-to-azurity-pharmaceuticals-300865696.html

    PR NEWSWIRE
    12 Jun 2019
    Share Share
    NovaQuest Capital Management acquires CutisPharma
    NovaQuest Capital Management acquires CutisPharma

    26 Mar 2018

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/novaquest-capital-management-acquires-cutispharma-inc-300619121.html

    PRNEWSWIRE
    26 Mar 2018
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search